Chemical stability of teniposide in aqueous and parenteral lipid emulsions

Drug Development and Industrial Pharmacy

Volumn 35, Issue 4, 2009, Pages 508-513

  Wang, Jing ^a   Cui, Yue ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Viscosity

Indexed keywords

LIPID EMULSION; TENIPOSIDE; ANTINEOPLASTIC AGENT; LIPID; WATER;

AQUEOUS SOLUTION; ARTICLE; DEGRADATION KINETICS; DRUG DEGRADATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH TEMPERATURE; PH; SHELF LIFE; VISCOSITY; CHEMISTRY; DRUG STORAGE; EMULSION; KINETICS; PHARMACEUTICS; SOLUTION AND SOLUBILITY; TEMPERATURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; EMULSIONS; HYDROGEN-ION CONCENTRATION; KINETICS; LIPIDS; SOLUTIONS; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; TENIPOSIDE; WATER;

EID: 65749119075     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802468016     Document Type: Article

References (25)

1. Akkar, A., & Müller, R. H. (2003). Formulation of intravenous carbamazepine emulsions by SolEmuls technology. Eur. J. Pharm. Biopharm., 55, 305-312. (Pubitemid 36561557)
2. Beijnen, J. H., Beijnen-Bandhoe, A. U., Dubbelman, A. C., Van Gijn, R., & Underberg, W. J. M. (1991). Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids. J. Parenter. Sci. Technol., 45, 108-112.
3. Beijnen, J. H., Holthuis, J. J. M., Kerkdijk, H. G., van der Houwen, O. A. G. J., Paalman, A. C. A., Bult, A., & Underberg, W. J. M. (1988). Degradation kinetics of etoposide in aqueous solution. Ind. J. Pharm. Sci., 41, 169-178.
4. Bjerregaard, S., Söderberg, I., Vermehrena, C., & Frokjaer, S. (1999). Formulation and evaluation of release and swelling mechanism of a water-in-oil emulsion using factorial design. Int. J. Pharm., 193, 1-11.
5. Dan, L. W. (2005). Evolution of parenteral lipid emulsions. Clin. Nutr. Suppl., 1,5 Floyd, A. G.
6. Floyd, A. G. (1999). Top ten considerations in the development of parenteral emulsions. Res. Focus, 2, 134-143.
7. Fukushima, S., Nakano, M., Takeuchi, Y., & Fukushima, M. (1997). Preparation of two dosage forms containing antitumor prostaglandin and their antitumor effect in vitro and in vivo: Lipiodol solution for i.a. administration and lipid microspheres for i.p. or i.v. administration. Adv. Exp. Med. Biol., 400B, 955-961.
8. Gordaliza, M., Castro, M. A., Miguel Del Corral, J. M., & San Feliciano, A. (2000). Antitumor properties of podophyllotoxin and related compounds. Curr. Pharm. Des., 6, 1811-1839.
9. Hammad, M. A., & Müller, B. W. (1998). Solubility and stability of clonazepam in mixed micelles. Int. J. Pharm., 169, 55-64.
10. Hayat, A.-O., & Kyounghee, S. (1992). Mixed micelles as proliposomes for the solubilization of teniposide. Pharm. Res., 9, 1556-1562.
11. Holthuis, J. J. M. (1988). Etoposide and teniposide bioanalysis, metabolism and clinical pharmacokinetics. Pharm. Weekbl. Sci., 10, 101-116.
12. Jafari, S. M., He, Y., & Bhandari, B. (2007). Production of sub-micron emulsions by ultrasound and micro fluidization techniques. J. Food Eng., 82, 478-488.
13. Jumaa, M., & Müller, B. W. (1998). The effect of oil components and homogenization conditions on the physicochemical properties and stability of parenteral fat emulsions. Int. J. Pharm., 163, 81-89.
14. Kenneth, R. H. (1998). Clinical application of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta., 1400, 173-184.
15. Krickau, D. P., Mueller, R. H., & Thomsen, J. (2007). Degradation kinetic of hydrolytically susceptible drugs in O/W emulsions-effects of interfacial area and lecithin. Int. J. Pharm., 342, 62-71.
16. Minotti, V., Crinò, L., Meacci, M. L., Corgna, E., Darwish, S., Palladino, M. A., Betti, M., & Tonato, M. (1998). Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer, 20, 93-98. (Pubitemid 28345190)
17. Mitsuko, T. (1996). Application of lipid microspheres for the treatment of cancer. Adv. Drug. Deliv. Rev., 20, 209-219.
18. Müller, R. H., Schmidt, S., Buttle, I., Akkar, A., Schmitt, J., & Brömer, S. (2004). SolEmuls1-novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Ind. J. Pharm. Sci., 269, 293-302.
19. Nagai1, N., Shikiia, T., Miharaa, K., Ogataa, H., & Sasakib, Y. (1998). Improved high-performance liquid chromatographic analysis of teniposide in human plasma. J. Chromatogr. B., 709, 315-319.
20. Santos Magalhaes, N. S., Cave, G., Seiller, M., & Benita, S. (1991). The stability and in vitro release kinetics of a clofibride emulsion. Int. J. Pharm., 76, 225-237.
21. Strong, D. K., & Morris, L. A. (1990). Precipitation of teniposide during infusion. Am. J. Hosp. Pharm., 47, 512.
22. Tamilvanan, S. (2004). Review oil in water lipid emulsion: Implications for parenteral and ocular delivering systems. Prog. Lipid. Res., 43, 489-533.
23. Venkateswarlu, V., & Patlolla, R. R. (2001). Lipid microspheres as drug delivery systems. Ind. J. Pharm. Sci., 63, 450-458.
24. Wang, Y. J. (2007). Formulation, preparation and evaluation of flunarizineloaded lipid microspheres. J. Pharm. Pharmacol., 59, 351-357.
25. Wang, J.-J., Sung, K. C., Hu, O. Y., Yeh, C.-H., & Fang, J.-Y. (2006). Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. J. Control. Release, 115, 140-149.